HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application for its generic version of Adoxa® (doxycyline monohydrate, 150 mg capsules). The Company is preparing for product launch through Global Pharmaceuticals, Impax’s generic division.
